Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FOMX

Menlo Therapeutics (FOMX) Stock Price, News & Analysis

Menlo Therapeutics logo

About Menlo Therapeutics Stock (NASDAQ:FOMX)

Advanced Chart

Key Stats

Today's Range
$2.99
$2.99
50-Day Range
$2.99
$2.99
52-Week Range
$1.97
$4.84
Volume
N/A
Average Volume
518,350 shs
Market Capitalization
$184.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Receive FOMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOMX Stock News Headlines

AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
Michael J. Fox Foundation taps Palo Alto AI firm
See More Headlines

FOMX Stock Analysis - Frequently Asked Questions

Menlo Therapeutics Inc. (NASDAQ:FOMX) released its quarterly earnings data on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07.

Based on aggregate information from My MarketBeat watchlists, some other companies that Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Bristol-Myers Squibb (BMY), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/11/2019
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & Botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:FOMX
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.16 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.60 million
Price / Cash Flow
N/A
Book Value
$1.70 per share
Price / Book
1.76

Miscellaneous

Free Float
N/A
Market Cap
$184.12 million
Optionable
Optionable
Beta
1.66
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:FOMX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners